{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:10:07Z","timestamp":1778202607384,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.urolonc.2026.111065","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:22:31Z","timestamp":1774671751000},"page":"176-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical trial participation in kidney, bladder, and prostate malignancies in the United States: Sociodemographic distribution and impact on survival"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-9338","authenticated-orcid":false,"given":"Onika D.V.","family":"Noel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burak","family":"Akgul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukund","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geeta","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshit","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Furkan","family":"Dursun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.urolonc.2026.111065_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205065","article-title":"Immunotherapies in genitourinary oncology: where are we now? Where are we going?","volume":"13","author":"Jang","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111065_bib0002","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111065_bib0003","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/107327481602300404","article-title":"Barriers to clinical trial enrollment in racial and Ethnic minority patients with cancer","volume":"23","author":"Hamel","year":"2016","journal-title":"Cancer Control"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111065_bib0004","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1353\/cpr.2012.0038","article-title":"Assessing an intervention to improve clinical trial perceptions among predominately African-American communities in South Carolina","volume":"6","author":"Ford","year":"2012","journal-title":"Prog Community Health Partnersh"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111065_bib0005","doi-asserted-by":"crossref","first-page":"208.e1","DOI":"10.1016\/j.urolonc.2023.01.022","article-title":"Factors associated with clinical trial participation for patients with renal cell carcinoma","volume":"41","author":"Shinder","year":"2023","journal-title":"Urol Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111065_bib0006","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1055-9965.EPI-19-1616","article-title":"Diversity of enrollment in prostate cancer clinical trials: current status and future directions","volume":"29","author":"Rencsok","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111065_bib0007","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1016\/j.urolonc.2026.111065_bib0008","doi-asserted-by":"crossref","first-page":"e1700","DOI":"10.1016\/S2214-109X(23)00406-0","article-title":"Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: a population-based study","volume":"11","author":"Frick","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.urolonc.2026.111065_bib0009","unstructured":"American College of Surgeons National Cancer Database. Accessed 2023 2020; Available from: https:\/\/www.facs.org\/Quality-Programs\/Cancer\/NCDB."},{"issue":"25","key":"10.1016\/j.urolonc.2026.111065_bib0010","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111065_bib0011","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"18","key":"10.1016\/j.urolonc.2026.111065_bib0012","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.23.01030","article-title":"National estimates of the participation of patients with cancer in clinical research studies based on Commission on Cancer Accreditation data","volume":"42","author":"Unger","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111065_bib0013","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamaoncol.2019.4097","article-title":"Overall survival in men with bone metastases from castration-resistant prostate cancer treated with bone-targeting radioisotopes: a meta-analysis of individual patient data from randomized clinical trials","volume":"6","author":"Terrisse","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111065_bib0014","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.adolescence.2012.10.004","article-title":"The mediating role of interpersonal competence between adolescents' empathy and friendship quality: a dyadic approach","volume":"36","author":"Chow","year":"2013","journal-title":"J Adolesc"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111065_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.27014","article-title":"Trends in chronic kidney disease care in the US by race and ethnicity, 2012-2019","volume":"4","author":"Chu","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"13","key":"10.1016\/j.urolonc.2026.111065_bib0016","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/cncr.30027","article-title":"Mind the gap: what is driving the survival disparity between the sexes in bladder cancer?","volume":"122","author":"Harshman","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111065_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100594","article-title":"Race, sex, and kidney disease trial participation","volume":"5","author":"Alahamadi","year":"2023","journal-title":"Kidney Med"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111065_bib0018","doi-asserted-by":"crossref","first-page":"199.e15","DOI":"10.1016\/j.urolonc.2022.03.013","article-title":"An evaluation of trends in the representation of patients by age, sex, and diverse race\/ethnic groups in bladder and kidney cancer clinical trials","volume":"40","author":"DesLoges","year":"2022","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111065_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2021.08.015","article-title":"Racial and socioeconomic disparities in CKD in the context of universal health care provided by the Military Health System","volume":"4","author":"Norton","year":"2022","journal-title":"Kidney Med"},{"issue":"8","key":"10.1016\/j.urolonc.2026.111065_bib0020","first-page":"1071","article-title":"Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review","volume":"33","author":"Freudenburg","year":"2022","journal-title":"Cancer Causes Control"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111065_bib0021","doi-asserted-by":"crossref","first-page":"e995","DOI":"10.1016\/j.clgc.2019.05.008","article-title":"Racial and socioeconomic disparities in bladder cancer survival: analysis of the California Cancer Registry","volume":"17","author":"Sung","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111065_bib0022","doi-asserted-by":"crossref","first-page":"195.e13","DOI":"10.1016\/j.urolonc.2021.11.015","article-title":"Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer","volume":"40","author":"Fletcher","year":"2022","journal-title":"Urol Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111065_bib0023","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1245\/s10434-024-15559-4","article-title":"Examining the concordance of patient age distribution between genitourinary (GU) clinical trials and real-world disease populations: kidney, prostate and bladder cancer analysis","volume":"31","author":"Helstrom","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111065_bib0024","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41391-023-00665-3","article-title":"Disparities in prostate cancer diagnosis and management: recognizing that disparities exist at all junctures along the prostate cancer journey","volume":"26","author":"Rais-Bahrami","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"10.1016\/j.urolonc.2026.111065_bib0025","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.6004\/jnccn.2014.0158","article-title":"Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer","volume":"12","author":"Behrendt","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2026.111065_bib0026","series-title":"National academies of sciences, e. and medicine, improving representation in clinical trials and research: building research equity for women and underrepresented groups","first-page":"280","year":"2022"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111065_bib0027","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/cncr.23201","article-title":"Disparities in participation in cancer clinical trials in the United States : a symptom of a healthcare system in crisis","volume":"112","author":"Colon-Otero","year":"2008","journal-title":"Cancer"},{"issue":"281","key":"10.1016\/j.urolonc.2026.111065_bib0028","article-title":"Promoting factors and barriers to participation in early phase clinical trials: patients perspectives","volume":"4","author":"Chalela","year":"2014","journal-title":"J Community Med Health Educ"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111065_bib0029","doi-asserted-by":"crossref","first-page":"e6905","DOI":"10.1002\/cam4.6905","article-title":"Effects of socioeconomic status on enrollment in clinical trials for cancer: a systematic review","volume":"13","author":"Donzo","year":"2024","journal-title":"Cancer Med"},{"issue":"21","key":"10.1016\/j.urolonc.2026.111065_bib0030","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.3390\/cancers16213559","article-title":"Striving for equity: examining health disparities in urologic oncology","volume":"16","author":"Puri","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"Suppl 2","key":"10.1016\/j.urolonc.2026.111065_bib0031","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1073274805012004S14","article-title":"Physician perspectives on cancer clinical trials and barriers to minority recruitment","volume":"12","author":"Hudson","year":"2005","journal-title":"Cancer Control"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111065_bib0032","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1186\/s12889-024-18353-9","article-title":"Changes in disease burden and global inequalities in bladder, kidney and prostate cancers from 1990 to 2019: a comparative analysis based on the global burden of disease study 2019","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Public Health"},{"issue":"5 Suppl 1","key":"10.1016\/j.urolonc.2026.111065_bib0033","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.ajkd.2018.06.021","article-title":"Kidney Disease among African Americans: a population perspective","volume":"72","author":"Laster","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111065_bib0034","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cncr.22436","article-title":"Provider roles in the recruitment of underrepresented populations to cancer clinical trials","volume":"109","author":"Howerton","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2026.111065_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100718","article-title":"Sociodemographic diversity in cancer clinical trials: new findings on the effect of race and ethnicity","volume":"21","author":"Meyer","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111065_bib0036","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae085","article-title":"Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer, 2011-2023","volume":"8","author":"Guadamuz","year":"2024","journal-title":"JNCI Cancer Spectr"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111065_bib0037","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6386","article-title":"Trends in health equity in the United States by race\/ethnicity, sex, and income, 1993-2017","volume":"2","author":"Zimmerman","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111065_bib0038","first-page":"93","article-title":"The Eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:28:53Z","timestamp":1778200133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1078143926000761"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111065","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trial participation in kidney, bladder, and prostate malignancies in the United States: Sociodemographic distribution and impact on survival","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}